Morgan Stanley assumes coverage on Zenas Biopharma stock with Overweight rating

Published 03/07/2025, 13:26
Morgan Stanley assumes coverage on Zenas Biopharma stock with Overweight rating

Investing.com - Morgan Stanley (NYSE:MS) has assumed coverage on Zenas Biopharma (NASDAQ:ZBIO) with an Overweight rating and a price target of $31.00. The target represents significant upside potential, with analyst targets ranging from $18 to $45. According to InvestingPro data, the stock appears undervalued based on its Fair Value analysis.

The research firm highlighted that Zenas Biopharma’s obexelimab inhibits B cells rather than depleting them, which could provide a potential advantage in autoimmune therapy treatments.

Morgan Stanley noted several upcoming catalysts for the biotech company, including Phase III INDIGO trial results for IgG4-RD expected by the end of 2025.

Additional data from the Phase II MoonStone trial in RMS is anticipated in early fourth quarter 2025, according to the coverage note.

The firm also mentioned that Phase II SunStone results in SLE, expected in mid-2026, could further validate the efficacy of obexelimab as a treatment option.

In other recent news, Zenas BioPharma announced the appointment of Haley Laken, Ph.D., as its new Chief Scientific Officer. Dr. Laken brings over two decades of experience in the biopharmaceutical industry, having held significant roles in translational research and drug development. Before joining Zenas, she served as the Chief Operating Officer at Tabby Therapeutics and held leadership positions at Jounce Therapeutics (NASDAQ:JNCE), TESARO, Rhythm Pharmaceuticals (NASDAQ:RYTM), Pfizer (NYSE:PFE), and Wyeth. Her primary focus at Zenas will be advancing the company’s lead product candidate, obexelimab, through Phase 2 and Phase 3 clinical trials. Obexelimab is being developed to treat autoimmune diseases such as IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company believes that obexelimab’s unique mechanism of action, which targets B cell lineage without depleting these cells, could provide clinical benefits to patients. Lisa von Moltke, Head of R&D and Chief Medical (TASE:BLWV) Officer at Zenas, expressed confidence in Dr. Laken’s expertise to enhance the company’s pipeline and development strategies. Dr. Laken also expressed enthusiasm for contributing to the progression of obexelimab at this pivotal time for Zenas. The company’s press release contains forward-looking statements regarding the potential benefits of obexelimab and pipeline expansion, though these are subject to risks and uncertainties.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.